Torigen Pharmaceuticals, Inc., a biotherapeutic company focused on treating cancer in animals announced today the commercialization and market launch of their product, VetiVax™.
VetiVax™ uses the patient’s own tumor cells to create a personalized treatment, which educates the patients immune system to recognize the tumor as foreign and attack the cancer.
Each year in the United States, over 6 million dogs and 6 million cats are diagnosed with cancer. Developed at the University of Notre Dame with over 10 years of supporting research, VetiVax™ is a whole cell tissue immunotherapy that allows for a variety of tumor antigens to be presented to the immune system. This treatment can be used for multiple tumor types.
Dr. Terry Dew of Azzore Veterinary Specialists in Russellville, Arkansas said. “With the use of VetiVax™ we have seen extended disease free intervals over what has been reported with chemo and radiation therapy for a wide range of tumor types. This combined with the fact that we have seen no significant adverse reactions makes VetiVaxTM a great compliment to surgical therapy.”
The company is focused on continuing a series of efficacy trials on selected cancer indications.